Half-year report · Q2
2934.TEDINET S100VCMY
Period2024-06-01 → 2024-11-30
Filed2025-03-06
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Amends S100V313. Amended by S100VCX6 (2025-03-06).
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.8bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Revenue | ¥17.7bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.0bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Operating income | ¥131m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Operating income | −¥221m | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Ordinary income | ¥112m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Ordinary income | −¥643m | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥232m | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥118m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Profit before tax | −¥233m | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥8m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.1bn | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥287m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥53m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Net income | −¥284m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Total assets | ¥9.1bn | at 2024-11-30 | Cons. | Assets |
| Total assets | ¥10.7bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥7.4bn | at 2023-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.5bn | at 2024-11-30 | Cons. | Liabilities |
| Total liabilities | ¥9.1bn | at 2024-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.7bn | at 2024-11-30 | Cons. | Net assets |
| Net assets / equity | ¥1.6bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2023-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.9bn | at 2024-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2023-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥13m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥971m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥220m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.8bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥300m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥139m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.4bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥933m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥1.58 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-426.06 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-59.33 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥1.56 | 2024-06-01 → 2024-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 12.7% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 10.8% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-06-01 → 2024-11-30 | −¥109m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-06-01 → 2024-11-30 | −¥109m |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2024-11-30 | −¥180m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥4.7bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥4.6bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥96m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥24m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥3.2bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥3.2bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥11m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥100m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥3.1bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥3.1bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥2m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥236m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2024-11-30 | ¥11.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2024-11-30 | ¥10.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥109m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2024-11-30 | ¥312m |
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2023-11-30 | −¥115m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2023-11-30 | −¥115m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-11-30 | −¥290m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥2.4bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥2.3bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥114m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥19m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥6m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥3.7bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥3.7bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥958,000 |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥44m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2023-11-30 | ¥8.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2023-11-30 | ¥8.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥115m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2023-11-30 | ¥69m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 533
| Item | Context | Value | Unit |
|---|---|---|---|
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式であります。なお、単元株式数は100株であります。 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)ジェイフロンティア株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都渋谷区桜丘町９番８号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes business combinations quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |